Stocks · Healthcare · Medical - Devices
Bio-Rad Laboratories, Inc. BIO
$369.14 +3.82% Close, Oct 2, 2026 · NYSE · Market cap $9.94B
Inexpensive vs sectorLow risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is in an uptrend: above its 200-day average for 61 trading days, with the 50-day average above the 200-day.
- Diluted EPS over the last four quarters was $8.25, down 29.7% year over year.
- Revenue over the last four quarters was $2.59B, up 1.4% from a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 32%
- EPS growth (TTM, YoY)Bottom 34%
- FCF growth (TTM, YoY)Bottom 40%
- Revenue growth, 3-year CAGRBottom 18%
- Revenue growth accelerationBottom 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 30%
- Gross marginBottom 35%
- Operating marginTop 28%
- Cash conversion (OCF / net income)Top 27%
- Accruals (lower is better)Bottom 28%
- Net debt / EBITDA (lower is better)Bottom 49%
- Interest coverTop 22%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 23%
- Free-cash-flow yieldTop 23%
- EBITDA / enterprise valueTop 22%
- Sales / enterprise valueTop 48%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 43%
- 6-month returnTop 31%
- 1-year return vs S&P 500Top 41%
- Distance from 52-week highTop 9%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 37%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 22%
- Upside to consensus price targetBottom 9%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 8%
- Maximum drawdown, 3 yearsTop 15%
- Beta vs S&P 500 (lower is better)Top 31%
- Net debt / EBITDA (lower is better)Bottom 49%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 1.9% | 1.4% | ↓ |
| Gross margin | 52.8% | 51.9% | ↓ |
| Operating margin | 8.8% | 9.1% | ↑ |
| FCF margin | 13.6% | 13.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 1.4% | 1.9% | ↓ | Bottom 32% |
| EPS growth (TTM, YoY) | -29.7% | — | Bottom 34% | |
| Gross margin | 51.9% | 52.8% | ↓ | Bottom 35% |
| Operating margin | 9.1% | 8.8% | ↑ | Top 28% |
| Net margin | 8.6% | 12.5% | ↓ | — |
| Free-cash-flow margin | 13.6% | 13.6% | ↑ | — |
| Return on invested capital | 1.5% | — | Top 30% | |
| Revenue growth, 3-year CAGR | -2.7% | — | Bottom 18% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 2.21×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -7.4 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 1.28×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 6.4×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.49%
- Net buyback yield (TTM)
- 0.46%
- Shareholder yield
- 0.96%
- Share count change, 1 year
- -1.5%
- Share count change, 3-year CAGR
- -3.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +10.4%
- Average 2-day reaction, last 8
- -1.2%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $350.00
- Target vs current price
- -5.2%
- Analysts with a rating
- 14
- Share rating Buy or Strong Buy
- 57%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +49.7% | -0.5% | +5.9% | +15.4% | — |
| Apr 30, 2026 | -4.1% | +1.8% | -5.9% | +15.7% | +15.0% |
| Feb 12, 2026 | -2.3% | -0.4% | -7.4% | -10.9% | -13.4% |
| Oct 29, 2025 | -1.7% | -3.3% | -5.9% | +0.5% | -9.4% |
| Jul 31, 2025 | +35.2% | -3.3% | +5.7% | +17.1% | +35.4% |
| May 1, 2025 | +46.8% | -1.5% | -4.7% | -6.7% | +3.7% |
| Feb 13, 2025 | +1.4% | -1.9% | -8.6% | -21.6% | -23.6% |
| Oct 30, 2024 | +57.0% | -0.3% | +12.9% | +1.8% | +10.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | $2.62 | $1.75 | +49.7% | $651.0M |
| Apr 30, 2026 | $1.89 | $1.97 | -4.1% | $592.1M |
| Feb 12, 2026 | $2.51 | $2.57 | -2.3% | $693.2M |
| Oct 29, 2025 | $2.26 | $2.30 | -1.7% | $653.0M |
| Jul 31, 2025 | $2.61 | $1.93 | +35.2% | $651.6M |
| May 1, 2025 | $2.54 | $1.73 | +46.8% | $585.4M |
| Feb 13, 2025 | $2.90 | $2.86 | +1.4% | $667.5M |
| Oct 30, 2024 | $2.01 | $1.28 | +57.0% | $649.7M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 44.7× | — | — | Top 23% |
| P/E (forward) | 38.1× | — | — | — |
| EV / EBITDA | 19.9× | — | — | Top 22% |
| EV / Sales | 4.10× | — | — | Top 48% |
| Free-cash-flow yield | 3.55% | — | — | Top 23% |
| Earnings yield | 2.23% | — | — | Top 23% |
P/E over the past five years
Range 3.6× – 46.1× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +23.9%
- Earnings per share growth (TTM)
- -29.7%
- Change in P/E multiple
- +796.7%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 1
- Days above the 200-day average
- 61
- 50-day average slope (20 days)
- +9.3%
- 200-day average slope (20 days)
- +2.0%
- Distance from 50-day average
- +1.0%
- Distance from 200-day average
- +20.0%
- RSI (14)
- 47.4
- Relative volume
- 0.83×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 28.5%
- Volatility vs own 5-year history
- 14th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.80
- Correlation with S&P 500
- 0.30
- Current drawdown from 1-year high
- -5.4%
- Maximum drawdown, 3 years
- -42.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 2, 2021 | Jun 2, 2025 | -73.8% | 939 days | Not yet recovered |
| Nov 6, 2020 | Nov 24, 2020 | -19.7% | 12 days | 53 days (Feb 11, 2021) |
| Feb 12, 2021 | Mar 8, 2021 | -16.3% | 15 days | 82 days (Jul 2, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $9.94B
- P/E (TTM)
- 44.7
- EPS, diluted (TTM)
- $8.25
- Revenue (TTM)
- $2.59B
- 52-week range
- $236.73 – $396.23
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Gross profit | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Operating income | $500.3M | $482.6M | $337.8M | $269.0M | $270.5M |
| Net income | $4.25B | -$3.63B | -$637.3M | -$1.84B | $759.9M |
| EPS (diluted) | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.87 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $649.7M | $667.5M | $585.4M | $651.6M | $653.0M | $693.2M | $592.1M | $651.0M |
| Net income | $653.2M | -$715.8M | $64.0M | $317.8M | -$341.9M | $720.0M | -$527.1M | $371.4M |
| EPS (diluted) | $23.34 | -$25.57 | $2.29 | $11.67 | -$12.70 | $26.65 | -$19.55 | $13.85 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $669.5M | $194.4M | $374.9M | $455.2M | $532.2M |
| Capital expenditure | -$133.7M | -$114.2M | -$156.7M | -$189.0M | -$157.6M |
| Free cash flow | $535.7M | $80.3M | $218.3M | $266.2M | $374.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$50.0M | -$215.7M | -$428.7M | -$203.6M | -$279.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.62B
- Total assets
- $10.25B
- Total liabilities
- $3.08B
- Total debt
- $1.20B
- Net debt
- $686.7M
- Shareholders’ equity
- $7.17B
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 998,654
- Days to cover
- 3.83
- Change vs previous report
- -11.7%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Mar 8, 2002
- 2-for-1
- Jun 3, 1996
- 3-for-2
- Jun 11, 1986
- 3-for-2
- Aug 1, 1985
- 3-for-2
- Mar 18, 1980
- 2-for-1